Evaluation of Treatment of Chronic HCV Patients in Chronic Kidney Disease Versus End Stage Renal Disease Patients

• Status: Completed
• Trial end date: 2018-05-01
• Target enrollment: 0
• Participant gender: All

Summary

1. To asses curability of( Ombitasvir ,Paritaprevir,Ritonavir) in chronic HCV infected patients in those with CKD versus ESRD in Assiut Hospital University .

2. Also assess duration of sustained viral response,treatment, relapse or failure of therapy in CKD versus ESRD in Assiut Hospital.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assiut University
• Treatments: Ritonavir

Criteria

Inclusion Criteria:

1. The patients aged from18- 60 years.

2. Chronic HCV infection with Plasma HCV RNA greater than 15,000 IU/mL

3. Treatment naïve.

4. compensated liver cirrhosis.

5. Absence of coinfection with HBV or HIV.

Exclusion Criteria:

1. Patients with hepatitis B virus or HIV.

2. prior antiviral therapy.

3. Haemoglobin level less than 10mg/dl.

4. Decompensated liver disease.